Emerging drugs for myelofibrosis

Expert Opinion on Emerging Drugs

Volumn 17, Issue 4, 2012, Pages 555-570

  Atallah, Ehab ^a   Verstovsek, Srdan ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Everolimus (RAD001); Fresolimumab (GC1008); GS 6624 (formerly AB0024); JAK 2 inhibitor; Momelotinib (CYT387); Myelofibrosis; Myeloproliferative neoplasm; Pacritinib (SB1518); Panobinostat (LBH589); Peg interferon; Pomalidomide (CC 4047); Ruxolitinib; SAR302503 (formerly TG101348)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANTIANEMIC AGENT; BMS 911543; BUSULFAN; CLADRIBINE; CORTICOSTEROID; DANAZOL; EVEROLIMUS; FRESOLIMUMAB; GANDOTINIB; GIVINOSTAT; GS 6624; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; MELPHALAN; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NS 018; PACRITINIB; PANOBINOSTAT; PEGINTERFERON ALPHA2A; PLACEBO; POMALIDOMIDE; PREDNISONE; RUXOLITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW SUPPRESSION; BONE PAIN; CACHEXIA; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DNA METHYLATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROID PRECURSOR CELL; FATIGUE; FOLLOW UP; GENE ACTIVITY; HEMATOPOIETIC CELL; HEPATOMEGALY; HISTONE MODIFICATION; HUMAN; HYPERKALEMIA; HYPERURICEMIA; LONG TERM CARE; MORTALITY; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OVERALL SURVIVAL; PATHOGENESIS; PERICARDIAL EFFUSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; PLEURA EFFUSION; PORTAL HYPERTENSION; PROGNOSIS; PRURITUS; RESPIRATORY DISTRESS; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN ULCER; SPLEEN DISEASE; SPLENECTOMY; SPLENOMEGALY; STEM CELL; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TUMOR LYSIS SYNDROME; VOMITING; XERODERMA;

ANEMIA; ANIMALS; CYTOKINES; DRUG DESIGN; HEMATOPOIESIS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PYRAZOLES; QUALITY OF LIFE; SPLENOMEGALY;

EID: 84870443079     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.748748     Document Type: Review

References (90)

1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001 - 2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51
3. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:284-93
4. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115:3842-7
5. Mesa RA, Green A, Barosi G, et al. MPN-associated myelofibrosis (MPNMF). Leuk Res 2011;35:12-13
6. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38
7. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011;2011:208-14
8. Le Bousse-Kerdiles MC, Martyre MC, Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 2008;19:69-80
9. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27
10. Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol Malig Rep 2009;4:33-40
11. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009;60:233-45
12. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70
13. Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010;115:4350-5
14. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31(6):737-40
15. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901
16. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-7
17. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8
18. Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nat Rev Drug Discov 2012;11:103-4
19. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109:68-76
20. Scherber RM, Dueck AC, Johansson P, et al. Symptomatic burden in myelofibrosis (MF): prospective international assessment in 128 MF patients. J Clin Oncol 2011;29(Suppl):abstract 6610
21. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011;2011:222-30
22. Tefferi A. How I treat myelofibrosis. Blood 2011;117:3494-504
23. Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010;116:3572-81
24. Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008;93:1514-22
25. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010;16:358-67
26. Stewart WA, Pearce R, Kirkland KE, et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010;45:1587-93
27. Siragusa S, Passamonti F, Cervantes F, Tefferi A. Survival in young patients with intermediate-/high-risk myelofibrosis: estimates derived from databases for non transplant patients. Am J Hematol 2009;84:140-3
28. Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012;120:1367-79
29. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005;105:4115-19
30. Kroger N, Alchalby H, Klyuchnikov E, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009;113:1866-8
31. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000;95:2226-33
32. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006;107:361-70
33. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7
34. Siragusa S, Vaidya R, Tefferi A. Hydroxyurea effect on marked splenomegaly associated with primary myelofibrosis: response rates and correlation with JAK2V617F allele burden. Available from: http://abstracts. hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/4971
35. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98
36. Barosi G, Grossi A, Comotti B, et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001;114:78-83
37. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-41
38. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116:4436-8
39. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-64
40. Abgrall JF, Guibaud I, Bastie JN, et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006;91:1027-32
41. Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011;118:899-902
42. Jakafi™ prescribing information. Incyte Corp. Available from: http://www.incyte.com/products/uspi-jakafi.pdf
43. Canada Newswire. (PR)JAKAVI® the first medication to receive Health Canada approval to treat patients with myelofibrosis. Available from: http://www.newswire.ca/en/story/1003655/-prjakavi-the-first-medication-to- receivehealth-canada-approval-to-treat-patientswith-myelofibrosis
44. Novartis. Novartis drug Jakavi® first medication to receive European Commission approval to treat patients with myelofibrosis. Available from: http://www.novartis.com/newsroom/media-releases/en/2012/1636508.shtml
45. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
46. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29
47. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130:709-15
48. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29:1356-63
49. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17
50. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188-91
51. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120:1202-9
52. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011;365:1455-7
53. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I [abstract 800]. ASH Annual Meeting;
54. Cervantes F, Kiladjian JJ, Niederwieser D, et al. Long-term safety, effiacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [abstract 801]. ASH Annual Meeting;
55. Talpaz M, Hamburg SI, Jamieson K, et al. Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50 - 100x109/L. J Clin Oncol 2012;30. Available from: http://meeting.ascopubs.org/cgi/content/abstract/30/15-suppl/6630?sid= 000067e3-547c-48cd-a5aa-31124951bede
56. YM BioSciences. Reports operational and financial results for the third quarter of fiscal 2012. Available from: http://www.ymbiosciences.com/investors/ Press-Releases/Press-Release-Details/2012/YMBioSciences-Reports-Operational-and- Financial-Results-for-the-Third-Quarterof-Fiscal-20121129442/default.aspx
57. Cell Therapeutics, Inc. Cell Therapeutics completes acquisition of pacritinib a highly selective JAK2 inhibitor; phase 3 study in patients with myelofibrosis and low platelet counts targeted to start in Q4-2012. Available from: http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p= irolnewsArticle&cat=news&id=1701881
58. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis. Blood 2010;115:1131-6
59. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20
60. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 2008;13:321-30
61. Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96
62. Pardanani AD, Cortes JE, Cervantes F, et al. JAKARTA: a phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly. J Clin Oncol 2012;30. Available from: http://meeting. ascopubs.org/cgi/content/abstract/30/15-suppl/TPS6639?sid=b31f33aad8e3-4ca7- bf1e-93a70dfb7858
63. Pardanani A, Lasho T, Smith G, et al. CYT387, a selective JAK1/ JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-5
64. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-40
65. Pardanani AD, Caramazza D, George G, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol 2011;29
66. Pardanani A, Gotlib J, Gupta V, et al. An expanded multicenter phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis. ASH Annual Meeting Abstr 2011;118:3849. Available from: http://abstracts. hematologylibrary.org/cgi/content/abstract/118/21/3849?maxtoshow=&hits= 10&RESULTFORMAT=1&author1=Pardanani&andorexacttitle= and&andorexacttitleabs=and&andorexactfulltext=and&searchid= 1&FIRSTINDEX=0&sortspec=relevance&volume=118&resourcetype=HWCIT
67. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-503
68. Gale RP, Barosi G, Barbui T, et al. What are RBC-tranfusion-dependence and -independence? Leuk Res 2011;35:8-11
69. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011;25:1751-9
70. Deeg HJ, Odenike O, Scott BL, et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. J Clin Oncol 2011;29(Suppl):abstract 6515
71. Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meeting Abstr 2011;118:282
72. Ma L, Zhao B, Walgren R, et al. Efficacy of LY2784544, a small molecule inhibitor selective for mutant JAK2 kinase, in JAK2 V617F-induced hematologic malignancy models. Available from: http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;116/21/4087
73. Verstovsek S, Mesa RA, Rhoades SK, et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Available from: http://abstracts. hematologylibrary.org/cgi/content/abstract/ashmtg;118/21/2814
74. Vannucchi AM, Bogani C, Bartalucci N, et al. The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. Available from: http://abstracts.hematologylibrary.org/cgi/content/abstract/ ashmtg;114/22/2914
75. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118:2069-76
76. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27:4563-9
77. Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010;85:129-30
78. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25:301-4
79. Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012;87:66-8
80. Mascarenhas J, Mercado A, Rodriguez A, et al. Prolonged low dose therapy with a pan-deacetylase inhibtor, panobinostat (LBH589), in patients with myelofibrosis. Available from: http://abstracts.hematologylibrary.org/cgi/ content/abstract/ashmtg;118/21/794
81. DeAngelo DJ, Tefferi A, Fiskus W, et al. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essentialtThrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis. Available from: http://abstracts. hematologylibrary.org/cgi/content/abstract/ashmtg;116/21/630
82. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the hdistone-eacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010;150:446-55
83. Odenike O, Godwin JE, van Besien K, et al. Phase II trial of decitabine in myelofibrosis with myeloid metaplasia J Clin Oncol. 2007;25(Suppl):7088
84. Barker HE, Erler JT. The potential for LOXL2 as a target for future cancer treatment. Future Oncol 2011;7:707-10
85. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-72
86. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006;108:2037-40
87. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011;117:4706-15
88. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24
89. Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 2009;146:223-5
90. Gowin K, Thapaliya P, Samuelsson J, et al. Experience with pegylated Interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012;97:1570-3